PMID- 34028406
OWN - NLM
STAT- MEDLINE
DCOM- 20211015
LR  - 20230925
IS  - 1536-0229 (Electronic)
IS  - 0363-9762 (Linking)
VI  - 46
IP  - 9
DP  - 2021 Sep 1
TI  - Prognostic Value of 18F-FDG PET in Neuroendocrine Neoplasm: A Systematic Review 
      and Meta-analysis.
PG  - 723-731
LID - 10.1097/RLU.0000000000003682 [doi]
AB  - OBJECTIVES: Accurate assessment of the prognosis is critical for the rational 
      treatment of neuroendocrine neoplasms (NENs). We performed a systematic review 
      and meta-analysis of the prognostic value of 18F-FDG PET for NENs. PATIENTS AND 
      METHODS: PubMed and Embase databases were searched up to September 2020 for 
      studies that evaluated 18F-FDG PET as prognostic factors in patients with NENs 
      with overall survival (OS) and event-free survival (EFS) as outcomes. Hazards 
      ratios (HRs) comparing high and low FDG uptakes were pooled using the 
      DerSimonian-Laird method. Publication bias was assessed and adjusted for using 
      the trim-and-fill method. Metaregression and subgroup analyses were performed to 
      explore the cause of heterogeneity. RESULTS: Twenty-three studies (1799 patients) 
      were included. The overall pooled HRs of high FDG uptake on EFS and OS were 2.84 
      (95% confidence interval [CI], 2.21-3.64) and 3.50 (95% CI, 2.42-4.12), 
      respectively. Publication biases were present regarding both EFS and OS (P = 
      0.0342 and 0.0009, respectively). After adjustment, effect sizes remained 
      significant for EFS and OS (adjusted HR, 2.26 [95% CI, 1.76-2.89]; 3.16 [95% CI, 
      2.42-4.12]). In metaregression analyses, the proportion of grade 3 tumors 
      positively correlated with the HR of OS (adjusted P = 0.0422). CONCLUSIONS: 
      18F-FDG PET is a significant prognostic factor in patients with NENs. 18F-FDG PET 
      might be a useful prognostic biomarker in conjunction with the histologic grade 
      and can help select the optimal treatment.
CI  - Copyright (c) 2021 Wolters Kluwer Health, Inc. All rights reserved.
FAU - Han, Sangwon
AU  - Han S
AD  - From the Department of Nuclear Medicine, Asan Medical Center, University of Ulsan 
      College of Medicine, Seoul.
FAU - Lee, Hyo Sang
AU  - Lee HS
AD  - Department of Nuclear Medicine, GangNeung Asan Hospital, University of Ulsan 
      College of Medicine, Gangneung, South Korea.
FAU - Woo, Sungmin
AU  - Woo S
AD  - Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY.
FAU - Kim, Tae-Hyung
AU  - Kim TH
FAU - Yoo, Changhoon
AU  - Yoo C
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, South Korea.
FAU - Ryoo, Baek-Yeol
AU  - Ryoo BY
AD  - Department of Oncology, Asan Medical Center, University of Ulsan College of 
      Medicine, Seoul, South Korea.
FAU - Ryu, Jin-Sook
AU  - Ryu JS
AD  - From the Department of Nuclear Medicine, Asan Medical Center, University of Ulsan 
      College of Medicine, Seoul.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
PL  - United States
TA  - Clin Nucl Med
JT  - Clinical nuclear medicine
JID - 7611109
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - *Fluorodeoxyglucose F18
MH  - Humans
MH  - *Neuroendocrine Tumors/diagnostic imaging
MH  - Positron Emission Tomography Computed Tomography
MH  - Prognosis
MH  - Radiopharmaceuticals
COIS- Conflicts of interest and sources of funding: none declared.
EDAT- 2021/05/25 06:00
MHDA- 2021/10/16 06:00
CRDT- 2021/05/24 12:26
PHST- 2021/05/25 06:00 [pubmed]
PHST- 2021/10/16 06:00 [medline]
PHST- 2021/05/24 12:26 [entrez]
AID - 00003072-202109000-00004 [pii]
AID - 10.1097/RLU.0000000000003682 [doi]
PST - ppublish
SO  - Clin Nucl Med. 2021 Sep 1;46(9):723-731. doi: 10.1097/RLU.0000000000003682.